http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2488585-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8d0579e29d73daff6d493b0ca378459 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54b91938b9c8bfc0ef66e5f17d26fee4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D451-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D451-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
| filingDate | 2008-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf2ba5ca6fffdb525b1684869138d8ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4921be6c9220f830da8d8e146c376f7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ef8556257d2445b3e391d7d5ced03ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5d87f24f2cf93e52fa3d25d7928969c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d27ca64b08d24e386cdb197ba1259ded http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3512a7fe5212437d2771903343e1c4c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4bffe2b44fe18cdd54086bda4950152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2583fb06320fc1cdf879f84e3987aed4 |
| publicationDate | 2013-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2488585-C2 |
| titleOfInvention | Substituted quinoxaline-type piperidine compounds and use thereof |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to substituted quinoxaline-type piperidine compounds of formula or to a pharmaceutically acceptable derivative thereof, wherein: Y 1 represents O; Q is specified in condensed benzo or pyridino; each R 2 is independently specified in: (a) -halogen or -CN; (b) -(C 1 -C 6 )alkyl; a is an integer specified in 0, 1 or 2; a dash line in a 6-member ring containing a nitrogen atom which is condensed with Q group means the presence or absence of a bond, and when the dash line means the absence of the bond, then R 3 , and one R 4 are absent; R 3 is specified in: (a) -H; each R 4 is independently specified in: (a) -H; or (b) - halogen or CN; or (c) -X, -(C 1 -C 6 )alkyl-X, -(5- or 6-member)heterocyclyl-X or -(5- or 6-member)heterocyclyl-(C 1 -C 6 )alkyl-X; or (d) -C(=Y)X, -C(=Y)T 3 , -C(=Y)YX, - C(=Y)YT 3 , -C(-Y)N(T 1 )(T 2 ), -C(=Y)N(R 9 )CN, -C(=Y)N(R 9 )X, -C(=Y)N(R 9 )YH, -C(=Y)N(R 9 )YX, -C(=Y)N(R 9 )YCH 2 X, -C(-Y)N(R 9 )YCH 2 CH 2 X or -C(=Y)N(R 9 )S(K)) 2 T 3 ; or (e) -N(R 9 )X, -N(R 9 )-CH 2 X, -N(R 9 )-CH 2 CH 2 X, -N(R 9 )CH 2 N(R 9 )C(=N(R 12 ))N(R 12 ) 2 , -N(R 9 )-CH 2 CH 2 N(R 9 )C(=N(R I2 ))N(R 12 ) 2 , -N(T 1 )(T 2 ), -N(T 3 )C(=Y)T 3 , -N(T 3 )C(=Y)YT 3 , -N(T 3 )C(=Y)N(T 1 )(T 2 ), -N(T 3 )S(=O) 2 T 3 or -N(T 3 )S(=O) 2 N(T 1 )(T 2 ); X represents: (a) -H, -( C 1 -C 6 )alkyl, -(C 2 -C 6 )alkenyl, -(C 1 -C 6 )alkoxy, -(C 3 -C 7 )cycloalkyl, -(5- or 6-member)heterocycle or -(7-10-member)bicycloheterocycle each of which is unsubstituted or substituted with 1, 2 or 3 of optionally substituted R 8 groups; or (b) -phenyl, -naphthalenyl, or -(5- or 6-member)heteroaryl each of which is unsubstituted or substituted with 1 or 2 of independently specified in R 7 groups; each Y is independently specified in O; A and B are independently specified in: (a) -H; or (c) A-B together can form a (C 2 -C 6 )bridge each can optionally contain -HC=CH- or -O- in a (C 2 -C 6 )bridge; wherein the 6-member ring containing a nitrogen atom which is condensed with Q group can be found in the endo- or exo- configuration in relation to the A-B bridge; or (d) A-B together can form the -CH 2 -N(R a )-CH 2 - bridge wherein the 6-member ring containing a nitrogen atom is condensed with Q group, and can be found in the endo- or exo- configuration in relation to the A-B bridge; R a is specified in -H or -(C 1 -C 6 )alkyl; Z represents -[(C 1 -C 10 )alkyl optionally substituted with R 1 ] h -, wherein h is equal to 0 or 1; each R 1 is independently specified in: (b) -(C 1 -C 10 )alkyl, -(C 2 -C 10 )alkenyl, -(C 2 -C 10 )alkynyl 3 -(C 3 -C 7 )cycloalkoxy, -(C 6 -C 14 )bicycloalkyl, -(C 8- C 10 )tricycloalkyl, -(C 5 -C 10 )cycloalkenyl, -(C 7 -C 14 )bicycloalkenyl, -(3-7-member)heterocyclyl each of which is unsubtituted or substituted with 1, 2 or 3 of independently specified in R 8 groups; n or or (d) -phenyl, -naphthalenyl each of which is unsubstituted or substituted with R 7 group; each R 6 is optionally specified in -H; each R 7 is independently specified in -(C 1 -C 4 )alkyl, -OR 9 , -C(halogen) 3 , -CH(halogen) 2 , -CH 2 (halogen), -CN, -halogen, -N(R 9 ) 2 , -C(=O)OR 9 ; each R 8 is independently specified in -(C 1 -C 4 alkyl, tetrzolyl, imidazolyl, furanyl, -(C 1 -C 6 )alkylCOOR 9 , -OR 9 , -SR 9 , -C(halogen) 3 , -CH(halogen) 2 , -CH 2 (halogen), -CN, =O, -halogen, -N(R 9 )(C 1 -C 6 )alkylCOOR 9 , -N(R 9 ) 2 , -N(R 9 )S(=O) 2 R 12 , -N(R 9 )C(=O)R 12 , -N(R 9 )C(=O)OR 12 , -C(=O)R 9 , -C(=O)N(T 1 )(T 2 ), -C(=O)OR 9 , -OC(=O)R 9 , or -S(=O) 2 R 9 ; each R 9 is independently specified in -H, -(C 1 -C 6 )alkyl, -(C 3 -C 8 )cycloalkyl, -phenyl, -benzyl, -(5- to 6-member)heterocycle, -C(halogen) 3 ; -CH(halogen) 2 or -CH 2 (halogen); if h is equal to O, then R 11 can be specified in -H, -C(=O)OR 9 or -C(=O)N(R 6 ) 2 or R 11 can be -(C 1 -C 4 )alkyl; if h is equal to 1, then R 11 can be specified in -H; each R 12 is independently specified in -H or -(C 1 -C 4 )alkyl; m is equal to an integer specified in 3, 4, 5, 6, 7, 8 or 9; each e and f is equal to an integer independently specified in 0 or 1, provided 2≤(e+f)≤5; each j and k is equal to an integer independently specified in 0 or 1, provided 1≤(j+k)≤4; each p is equal to an integer independently specified in 0 or 1; each T 1 , T 2 , and T 3 is independently specified in -H or -(C 1 -C 10 )alkyl which is unsubstituted or substituted with 1, 2 or 3 from independently specified R 8 groups, or T 1 and T 2 together can form 5- to 8-member ring wherein the number of ring atoms contains a nitrogen atom wherein T 1 and T 2 are bound; the above 5- to 8-member ring is unsubstituted or substituted with 1, 2 or 3 from independently specified R 8 groups and optionally any carbon atom in the above 5- to 8-member ring is independently substituted with O or N(R 6 ); each halogen is independently specified in -F, -CI, -Br or -I. n EFFECT: invention refers to the intermediate compounds of formula n , , for preparing the above compounds of formula (II), compositions containing the above compounds and to a method of treating or preventing a diseased state, such as a pain. n 36 cl, 58 ex, 2 tbl |
| priorityDate | 2007-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.